Summary
Glioblastoma Multiform (GBM) patients usually die 12-18 months after diagnosis, with a 5-year survival rate of 6.8%. There are only 5 therapies approved to treat GBM and all of them provide marginal improvements of
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190184696 |
| Start date: | 01-01-2023 |
| End date: | 31-12-2025 |
| Total budget - Public funding: | 21 516 125,00 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Glioblastoma Multiform (GBM) patients usually die 12-18 months after diagnosis, with a 5-year survival rate of 6.8%. There are only 5 therapies approved to treat GBM and all of them provide marginal improvements ofStatus
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
